Traws Pharma, Inc.
TRAWNASDAQHealthcare● Active
$1.37
+$0.00(+0.00%)
Market Cap$12522441
P/E Ratio—
52W High$3.27
52W Low$1
Traws Pharma, Inc. (TRAW) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TRAW · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.79M | $0.23M | $0.23M | $0.23M | $0.23M |
| Cost of Revenue | $0.00M | $0.01M | $0.00M | $0.00M | $0.00M |
| Gross Profit | $2.79M | $0.21M | $0.23M | $0.23M | $0.23M |
| Gross Margin %(computed) | 100.00% | 94.69% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $12.14M | $130.31M | $11.43M | $11.41M | $7.30M |
| G&A Expenses | $8.52M | $12.29M | $9.09M | $8.45M | $9.43M |
| Total Operating Expenses | $20.66M | $49.56M | $20.52M | $19.85M | $16.72M |
| Operating Income | ($17.88M) | ($49.35M) | ($20.30M) | ($19.63M) | ($16.50M) |
| Operating Margin %(computed) | -640.68% | — | — | — | — |
| Interest Income | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | $9.17M | ($166.52M) | ($18.95M) | ($18.96M) | ($16.16M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | $9.17M | ($54.67M) | ($18.95M) | ($18.96M) | ($16.16M) |
| Net Margin %(computed) | 328.67% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $0.83 | $-35.21 | $-22.57 | $-22.68 | $-24.01 |
| Wtd Avg Shares | 8.23M | 1.55M | 0.84M | 0.84M | 0.67M |
| EBITDA | ($17.81M) | ($166.51M) | ($20.28M) | ($19.61M) | ($16.48M) |
| EBITDA Margin %(computed) | -638.49% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Traws Pharma, Inc. data
About Traws Pharma, Inc. (TRAW) Income Statement
Traws Pharma, Inc. (TRAW) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, TRAW reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of $0.01B — a net profit margin of 328.67%.
Frequently asked questions
TRAW · 4 questionsTraws Pharma, Inc. (TRAW) reported revenue of $0.00B for 2025, up 1134.5% year-over-year.
TRAW revenueTRAW salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08